2-benzyl-3-methyl-butyric acid tert-butyl ester | 132129-17-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-benzyl-3-methyl-butyric acid tert-butyl ester
• 英文别名: 2-Benzyl-3-methyl-buttersaeure-tert-butylester；Tert-butyl 2-benzyl-3-methylbutanoate
• CAS: 132129-17-0
• 化学式: C₁₆H₂₄O₂
• 分子量: 248.365
• InChiKey: SRQBOPRALUFGSN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  氯化苄 、 alkaline earth salt of/the/ methylsulfuric acid 在 lithium amide 、 乙醚 、 氨 作用下， 生成 2-benzyl-3-methyl-butyric acid tert-butyl ester
  参考文献：
  名称：

  Condensation of t-Butyl Esters with Organic Halides in the Presence of Alkali Amides

  摘要：

  DOI：

  10.1021/ja01530a066

文献信息

• [EN] COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONS<br/>[FR] COMPOSÉS POUR LA RÉDUCTION DE LA VISCOSITÉ DE FORMULATIONS BIOLOGIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2019050780A1

  公开（公告）日：2019-03-14

  The present invention relates to pegylated amino acid compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3A, R3B and n are as defined herein. The present invention also relates to compositions which comprise a pegylated amino acid compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, in combination with a high concentration of an active biological ingredient (ABI). In embodiments of the invention, the ABI is an anti-PD-1 antibody or antigen binding fragment thereof that specifically binds human programmed death receptor 1 (PD-1). The invention further relates to methods for lowering the viscosity of an aqueous solution of a pharmaceutical composition comprising adding a compound of the invention to the solution. The invention also provides methods for treating a pathological disease or condition, such as cancer, by administering to a subject in need of such treatment a therapeutically effective amount of a pharmaceutical composition of the invention.

  本发明涉及公式（I）的聚乙二醇化氨基酸化合物及其药学上可接受的盐，其中X、R1、R2、R3A、R3B和n如本文所定义。本发明还涉及包含本发明的聚乙二醇化氨基酸化合物或其药学上可接受的盐以及药学上可接受的载体的组合物，与高浓度的活性生物成分（ABI）结合。在本发明的实施例中，ABI是特异性结合人类程序性死亡受体1（PD-1）的抗PD-1抗体或其抗原结合片段。本发明还涉及降低含有本发明化合物的药物组合物水溶液粘度的方法，包括向溶液中添加本发明的化合物。本发明还提供了治疗病理性疾病或病况（如癌症）的方法，通过向需要此类治疗的受试者投予本发明的药物组合物的治疗有效量。
• COMPOUND OR SALT THEREOF AND PREPARATION METHOD AND APPLICATION OF SAME
  申请人：ZHEJIANG PEPTITES BIOTECH CO., LTD.

  公开号：US20210277051A1

  公开（公告）日：2021-09-09

  The invention relates to a compound or a salt thereof, a method for preparation thereof, and use thereof, wherein the compound has the structure of Formula (1): the substituents in Formula (1) are as defined in the specification. The compound of Formula (1) or a salt thereof can be attached to a solid-phase resin, on which solid-phase synthesis may be performed.